1 insider bought shares over the last 90 days, the latest by HSBC Mutual Fund, filed 20 Aug 2026.
Thyrocare Technologies Limited belongs to the Technology sector. Filings by its managers are published through SEBI (PIT + SAST). The last twelve months, up to 23 October 2026, brought 66 filings signed by 37 insiders.
Both sides are active: 34 purchases worth €149k and 26 sales worth €154.5M, from 17 insiders and 19 insiders respectively. The amount is not disclosed for 3 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Docon Technologies Private Limited filed the largest sale, €74.1M, on 13 August 2026, which represents 9.0% of the company's market value.
Compared with its exchange (1,891 companies, median 4 filings), a count of 66 filings is above the norm. The full history, which starts in 2021, counts 44 purchases against 28 sales.
In the case of 31 purchases, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The clock since the last published purchase (20 August 2026) now reads 65 days. Filings reach the SEBI (PIT + SAST) feed a median of 1 day after the trade. This delay matters because a trade only becomes useful information once it is public.
Other companies in the same sector with recent insider buying flagged by our signals: Hanza AB and Lime Technologies AB (publ). This summary is built from SEBI (PIT + SAST) disclosures alone and does not predict where the share price will go.
+26 other insiders
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Thyrocare Technologies Limited Strong Buy (bullish), based on 5 analysts. Average price target: ₹681.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended March 2026 · cache
25 of 96 declarations
Thyrocare Technologies Limited is a company specializing in medical diagnostic services and laboratory testing. It offers a wide range of health tests, including hormonal tests and screening tests.
Purchases our model currently ranks for the recommendations list.
All recommendations